Legrand MA, Millet M, Merle B, et al. - In view of the gap in knowledge concerning fibrous dysplasia (FD) pathogenesis, the absence of prognostic markers and the lack of specific treatment, researchers sought the specific biomarkers of FD in order to improve the clinical and therapeutic approaches. Circulating microRNAs (miRNAs) are sought that are differentially expressed in FD patients compared with controls and would indicate dysregulations of osteogenesis‐related genes and bone disorder. They observed significant overexpression of six miRNAs (miR‐25‐3p, 93‐5p, 182‐5p, 324‐5p, 363‐ 3p and 451a) in serum, with FDR < 0.05. No association was observed of the expression level of these six miRNAs with the FD severity. A signature of circulating miRNAs associated with FD was thus identified in this study. In bone cell progenitors, these miRNAs are potential negative regulators of gene expression indicating their activity in FD by interfering with osteoblastic and osteoclastic differentiation to impair bone mineralization and remodeling processes.